Daratumumab with or without chemotherapy in relapsed and refractory acute lymphoblastic leukemia. A retrospective observational Campus ALL study

Abstract

Not available.

Case report: Daratumumab treatment in pre-transplant alloimmunization and severe hemolytic anemia

“…(phase 2 DELPHINUS study - oral abstract) and Cerrano et al. recently published early results of the addition of DARA to re-induction therapy for relapsed/refractory T-ALL and lymphoblastic lymphoma showing improved response rates with manageable adverse events ( 36 ). In pediatrics, there is an ongoing clinical trial investigating the role of DARA in addition to standard chemotherapy for relapsed/refractory T or B cell ALL (NCT03384654).…”

Daratumumab‐induced minimal residual disease negative remission in CD38 (dim)‐positive pediatric acute myeloid leukemia

“…Leukemic blasts commonly express CD38.Daratumumab.a recombinant monoclonal antihuman CD38 antibody approved for myeloma therapyhas been suggested to be potent in acute lymphoblastic leukemia. 3 We report the possibly first case of pediatric AML to achieveMRD negative remission with single agent daratumumab.…”

Daratumumab induced Minimal Residual Disease Negative Remission in CD 38 (dim) Positive Pediatric Acute Myeloid Leukemia

“…Leukemic blasts commonly express CD38, daratumumab, a recombinant monoclonal antihuman CD38 antibody approved for myeloma therapy, has been suggested to be also potent in acute lymphoblastic leukemia. 3 We report possibly first case of pediatric AML who achieved MRD negative remission with single agent daratumumab.…”